Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2014-04-23

FDA Approved: SYLVANT — Original Application (Recordati Rare Diseases, Inc.)

View source ↗

Summary

The FDA approved Sylvant (siltuximab) under the original application by Recordati Rare Diseases, Inc. for idiopathic multicentric Castleman disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sylvant (siltuximab)

Snippet

ORIG AP for SYLVANT (SILTUXIMAB)